全文获取类型
收费全文 | 4521篇 |
免费 | 471篇 |
国内免费 | 29篇 |
专业分类
耳鼻咽喉 | 34篇 |
儿科学 | 115篇 |
妇产科学 | 41篇 |
基础医学 | 484篇 |
口腔科学 | 196篇 |
临床医学 | 565篇 |
内科学 | 995篇 |
皮肤病学 | 98篇 |
神经病学 | 361篇 |
特种医学 | 476篇 |
外科学 | 880篇 |
综合类 | 29篇 |
预防医学 | 358篇 |
眼科学 | 40篇 |
药学 | 136篇 |
中国医学 | 4篇 |
肿瘤学 | 209篇 |
出版年
2023年 | 87篇 |
2022年 | 62篇 |
2021年 | 135篇 |
2020年 | 105篇 |
2019年 | 131篇 |
2018年 | 174篇 |
2017年 | 123篇 |
2016年 | 156篇 |
2015年 | 179篇 |
2014年 | 224篇 |
2013年 | 243篇 |
2012年 | 255篇 |
2011年 | 266篇 |
2010年 | 153篇 |
2009年 | 198篇 |
2008年 | 173篇 |
2007年 | 208篇 |
2006年 | 193篇 |
2005年 | 165篇 |
2004年 | 107篇 |
2003年 | 109篇 |
2002年 | 95篇 |
2001年 | 76篇 |
2000年 | 66篇 |
1999年 | 77篇 |
1998年 | 82篇 |
1997年 | 105篇 |
1996年 | 93篇 |
1995年 | 74篇 |
1994年 | 72篇 |
1993年 | 70篇 |
1992年 | 49篇 |
1991年 | 47篇 |
1990年 | 60篇 |
1989年 | 69篇 |
1988年 | 45篇 |
1987年 | 45篇 |
1986年 | 45篇 |
1985年 | 45篇 |
1984年 | 19篇 |
1983年 | 26篇 |
1982年 | 31篇 |
1981年 | 34篇 |
1980年 | 21篇 |
1979年 | 23篇 |
1978年 | 15篇 |
1977年 | 17篇 |
1976年 | 19篇 |
1975年 | 13篇 |
1971年 | 9篇 |
排序方式: 共有5021条查询结果,搜索用时 929 毫秒
81.
Maximilian Ackermann Brent A. Morse Vera Delventhal Irvith M. Carvajal Moritz A. Konerding 《Angiogenesis》2012,15(4):685-695
Increasing experimental evidence suggests that IGF-1 may modulate tumor angiogenesis via activation of the expression of VEGF in Ewing sarcomas and rhabdomyosarcomas. This study investigates the effects of the PEGylated Adnectins? CT-322, a VEGFR2-inhibitor and AT580Peg40, an IGF-1R inhibitor, as monotherapy and in combination in a murine A673 xenograft tumor model. The combination of Adnectins CT-322 and AT580Peg40 revealed a 83?% reduction in tumor growth, a nearly 5 times lower vessel density, less necrotic areas and less appearance of intussusceptive angiogenesis. Monotherapy with IGF-1R or CT-322 revealed equally a significant inhibition of tumor and vessel growth. Combinatory inhibition of IGF-1R and VEGFR2 shows a downregulation of IGF-binding protein 2 and a compensatory upregulation of VEGF levels. Immunohistological analysis showed remodeling vascular effects of CT-322-treatment or combination therapy. The vascular architecture in Adnectin-treated tumors was characterized by a strong normalization of vasculature. 3D-evaluation in microvascular corrosion casts showed significantly higher intervascular and interbranching distances in Adnectin-treated tumors. CT-322-treatment and combinatory inhibition reveal a significant reduction of intussusceptive angiogenesis. These pronounced effects on tumor vasculature suggest potential therapeutic benefit of combinatorial IGF1- and VEGF- pathways inhibition in Ewing’s sarcoma. 相似文献
82.
83.
84.
85.
A diaper bank and home visiting partnership: Initial exploration of research and policy questions
下载免费PDF全文
![点击此处可从《Public health nursing (Boston, Mass.)》网站下载免费的PDF全文](/ch/ext_images/free.gif)
86.
87.
Femoroacetabular impingement (FAI) is a pathomechanical concept describing the early and painful contact of morphological changes of the hip joint, both on the acetabular, and femoral head sides. These can lead clinically to symptoms of hip and groin pain, and a limited range of motion with labral, chondral and bony lesions. 相似文献
88.
Garcia S Moritz TE Ward HB Pierpont G Goldman S Larsen GC Littooy F Krupski W Thottapurathu L Reda DJ McFalls EO 《The American journal of cardiology》2008,102(7):809-813
The Coronary Artery Revascularization Prophylaxis (CARP) study showed no survival benefit with preoperative coronary artery revascularization before elective vascular surgery. The generalizability of the trial results to all patients with multivessel coronary artery disease (CAD) has been questioned. The objective of this study was to determine the impact of prophylactic coronary revascularization on long-term survival in patients with multivessel CAD. Over a 4-year period, 1,048 patients underwent coronary angiography before vascular surgery during screening into the CARP trial. The cohort was composed of registry (n = 586) and randomized (n = 462) patients, and their survival was determined at 2.5 years after vascular surgery. High-risk coronary anatomy without previous bypass surgery included 2-vessel disease (n = 204 [19.5%]), 3-vessel disease (n = 130 [12.4%]), and left main coronary artery stenosis >/=50% (n = 48 [4.6%]). By log-rank test, preoperative revascularization was associated with improved survival in patients with a left main coronary artery stenoses (0.84 vs 0.52, p <0.01) but not those with either 2-vessel (0.80 vs 0.79, p = 0.83) or 3-vessel (0.79 vs 0.71, p = 0.15) disease. In conclusion, unprotected left main coronary artery disease was present in 4.6% of patients who underwent coronary angiography before vascular surgery, and this was the only subset of patients showing a benefit with preoperative coronary artery revascularization. 相似文献
89.
Miodrag Dodic Karen Moritz Irene Koukoulas E Marelyn Wintour 《Trends in Endocrinology and Metabolism》2002,13(9):403-408
The results from numerous epidemiological studies suggested that there was a link between low birth weight (low for gestational age) and development of high blood pressure in adulthood. More recently, it has been shown that one important determinant is the early exposure of the developing fetus to excess glucocorticoid (GC). Hypertension develops in adult sheep and rats that are exposed to excess GC at a stage in gestation when both kidney and brain are still extremely primitive organs. Here, we propose that permanent changes in gene expression and function of these two organs could be crucial in the development of adult-onset hypertension as a result of prenatal GC exposure. 相似文献
90.
Brandon P. Verdoorn MD Tamara K. Evans BS Gregory J. Hanson MD Yi Zhu PhD Larissa G. P. Langhi Prata PhD Robert J. Pignolo MD PhD Elizabeth J. Atkinson MS Erin O. Wissler-Gerdes MA George A. Kuchel MD Joan B. Mannick MD Stephen B. Kritchevsky PhD Sundeep Khosla MD Stacey A. Rizza MD Jeremy D. Walston MD Nicolas Musi MD Lewis A. Lipsitz MD Douglas P. Kiel MD Raymond Yung MB ChB Nathan K. LeBrasseur PhD Ravinder J. Singh PhD Teresa McCarthy MD MS Michael A. Puskarich MD Laura J. Niedernhofer MD PhD Paul D. Robbins PhD Matthew Sorenson JD MA Tamara Tchkonia PhD James L. Kirkland MD PhD 《Journal of the American Geriatrics Society》2021,69(11):3023-3033
The burden of senescent cells (SnCs), which do not divide but are metabolically active and resistant to death by apoptosis, is increased in older adults and those with chronic diseases. These individuals are also at the greatest risk for morbidity and mortality from SARS-CoV-2 infection. SARS-CoV-2 complications include cytokine storm and multiorgan failure mediated by the same factors as often produced by SnCs through their senescence-associated secretory phenotype (SASP). The SASP can be amplified by infection-related pathogen-associated molecular profile factors. Senolytic agents, such as Fisetin, selectively eliminate SnCs and delay, prevent, or alleviate multiple disorders in aged experimental animals and animal models of human chronic diseases, including obesity, diabetes, and respiratory diseases. Senolytics are now in clinical trials for multiple conditions linked to SnCs, including frailty; obesity/diabetes; osteoporosis; and cardiovascular, kidney, and lung diseases, which are also risk factors for SARS-CoV-2 morbidity and mortality. A clinical trial is underway to test if senolytics decrease SARS-CoV-2 progression and morbidity in hospitalized older adults. We describe here a National Institutes of Health-funded, multicenter, placebo-controlled clinical trial of Fisetin for older adult skilled nursing facility (SNF) residents who have been, or become, SARS-CoV-2 rtPCR-positive, including the rationale for targeting fundamental aging mechanisms in such patients. We consider logistic challenges of conducting trials in long-term care settings in the SARS-CoV-2 era, including restricted access, consent procedures, methods for obtaining biospecimens and clinical data, staffing, investigational product administration issues, and potential solutions for these challenges. We propose developing a national network of SNFs engaged in interventional clinical trials. 相似文献